Dehydrovomifoliol Alleviates Nonalcoholic Fatty Liver Disease via the E2F1/AKT/mTOR Axis: Pharmacophore Modeling and Molecular Docking Study

Figure 3

Pharmacophore structure analysis of dehydrovomifoliol and the seven receptor targets involved in NAFLD treatment using the PharmMapper database. (a) Pharmacophore models for the interaction of E2F1 with dehydrovomifoliol. (b) Pharmacophore models for the interaction of MERTK with dehydrovomifoliol. (c) Pharmacophore models for the interaction of SOX17 with dehydrovomifoliol. (d) Pharmacophore models for the interaction of MMP9 with dehydrovomifoliol. (e) Pharmacophore models for the interaction of SULT2A1 with dehydrovomifoliol. (f) Pharmacophore models for the interaction of VEGFA with dehydrovomifoliol. (g) Pharmacophore models for the interaction of BLVRA with dehydrovomifoliol. (h) Pharmacophore models for the interaction of E2F1, MERTK, SOX17, MMP9, SULT2A1, VEGFA, and BLVRA with dehydrovomifoliol.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)